TScan Therapeutics (TCRX)
(Delayed Data from NSDQ)
$8.48 USD
-0.07 (-0.82%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $8.46 -0.02 (-0.24%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
TCRX 8.48 -0.07(-0.82%)
Will TCRX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for TCRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TCRX
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
TCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
Other News for TCRX
Buy Rating Affirmed for TScan Therapeutics Amidst Promising Clinical Advancements
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
TScan Therapeutics receives FDA's RMAT designation for two TCR-T candidates
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults